MEDSURGE MUPIROCIN NASAL OINTMENT mupirocin (as calcium) 20 mg/g (2% w/w) ointment tube Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge mupirocin nasal ointment mupirocin (as calcium) 20 mg/g (2% w/w) ointment tube

medsurge pharma pty ltd - mupirocin calcium, quantity: 21.5 mg/g (equivalent: mupirocin, qty 20 mg/g) - ointment - excipient ingredients: white soft paraffin; bis-diglyceryl polyacyladipate-2 - medsurge mupirocin nasal ointment is indicated for the elimination of nasal carriage of staphylococci, including methicillin resistant staphylococcus aureus (mrsa).

CLONIDINE HCI INJECTION MEDSURGE clonidine hydrochloride 150 microgram/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

clonidine hci injection medsurge clonidine hydrochloride 150 microgram/1 ml solution for injection ampoule

medsurge pharma pty ltd - clonidine hydrochloride, quantity: 150 microgram/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - clonidine hci injection medsurge is indicated for acute hypertensive crisis and as an alternative to oral therapy where the oral route of administration is inappropriate.

TRANEXAMIC ACID INJECTION MEDSURGE tranexamic acid 500 mg/5 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

tranexamic acid injection medsurge tranexamic acid 500 mg/5 ml solution for injection ampoule

medsurge pharma pty ltd - tranexamic acid, quantity: 500 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - intravenous administration,adults,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

MEDSURGE HYDROMORPHONE HP 10 mg/1 mL hydromorphone hydrochloride 10 mg/1 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge hydromorphone hp 10 mg/1 ml hydromorphone hydrochloride 10 mg/1 ml injection ampoule

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium citrate dihydrate; sodium chloride; citric acid; sodium hydroxide - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

MEDSURGE HYDROMORPHONE 2 mg/1 mL hydromorphone hydrochloride 2 mg/1 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge hydromorphone 2 mg/1 ml hydromorphone hydrochloride 2 mg/1 ml injection ampoule

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 2 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; citric acid; sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

MEDSURGE HYDROMORPHONE XHP 50 mg/1 mL hydromorphone hydrochloride 50 mg/1 mL concentrated injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge hydromorphone xhp 50 mg/1 ml hydromorphone hydrochloride 50 mg/1 ml concentrated injection ampoule

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 50 mg - injection, concentrated - excipient ingredients: citric acid; sodium chloride; sodium citrate dihydrate; water for injections; hydrochloric acid; sodium hydroxide - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

MEDSURGE HYDROMORPHONE HP 20 mg/1 mL hydromorphone hydrochloride 20 mg/1 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge hydromorphone hp 20 mg/1 ml hydromorphone hydrochloride 20 mg/1 ml injection ampoule

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid; hydrochloric acid; sodium hydroxide; sodium citrate dihydrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

MEDSURGE HYDROMORPHONE HP 100 mg/10 mL hydromorphone hydrochloride 100 mg/10 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge hydromorphone hp 100 mg/10 ml hydromorphone hydrochloride 100 mg/10 ml injection ampoule

medsurge pharma pty ltd - hydromorphone hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide; citric acid; sodium citrate dihydrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

KETOROLAC MEDSURGE ketorolac trometamol 10 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac medsurge ketorolac trometamol 10 mg/1 ml solution for injection ampoule

medsurge pharma pty ltd - ketorolac trometamol, quantity: 10 mg - injection - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid; ethanol - ketorolac medsurge solution for injection is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the section 4.2 dose and method of administration (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. note that oral dosage forms are available from other brands.,general,ketorolac medsurge solution for injection is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac medsurge solution for injection in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

KETOROLAC MEDSURGE ketorolac trometamol 30 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac medsurge ketorolac trometamol 30 mg/1 ml solution for injection ampoule

medsurge pharma pty ltd - ketorolac trometamol, quantity: 30 mg - injection - excipient ingredients: sodium chloride; ethanol; sodium hydroxide; hydrochloric acid; water for injections - ketorolac medsurge solution for injection is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the section 4.2 dose and method of administration (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. note that oral dosage forms are available from other brands.,general,ketorolac medsurge solution for injection is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac medsurge solution for injection in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).